Clinical next generation sequencing for precision medicine in cancer

Current Genomics

Volumn 16, Issue 4, 2015, Pages 253-263

  Dong, Ling ^a   Wang, Wanheng ^b   Li, Alvin ^a   Kansal, Rina ^a   Chen, Yuhan ^d   Chen, Hong ^c   Li, Xinmin ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Shanxi Guoxin Caregeno Medical Laboratories   (China)

^c Qiqihaer First Hospital   (China)

^d HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Cancer; Gene panel; Next generation sequencing; Precision medicine; Whole exome sequencing

Indexed keywords

B RAF KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR;

ACTIONABLE GENE PANEL; ARTICLE; COMPREHENSIVE PANEL; DISEASE FOCUSED PANEL; GENE; GENE MUTATION; GENE SEQUENCE; GENOMICS; HOTSPOT PANEL; HUMAN; KRAS GENE; LUNG CANCER; NEOPLASM; NEXT GENERATION SEQUENCING; PANCREAS CANCER; PERSONALIZED MEDICINE; PRECISION MEDICINE; THYROID CANCER; WHOLE EXOME SEQUENCING; WHOLE GENOME SEQUENCING;

EID: 84935073981     PISSN: 13892029     EISSN: 18755488     Source Type: Journal    
DOI: 10.2174/1389202915666150511205313     Document Type: Article

References (46)

1. National Research Council. Toward precision medicine: building aknowledge network for biomedical research and a new taxonomy of disease. Washington, DC: National Academies Press. www.nap.edu/catalog/13284/toward-precision-medicine-building-a-knowledge-network-for-biomedical-research (Accessed November 2, 2011).
2. Garraway, L.A. Genomics-driven oncology: Framework for an emerging paradigm. J. Clin. Oncol., 2013, 3, 1806-1814.
3. Karapetis, C.S.; Khambata-Ford, S.; Jonker D.J.; O'Callaghan, C.J.; Tu D.; Tebbutt, N.C.; Simes, R.J.; Chalchal, H.; Shapiro, J.D.; Robitaille, S.; Price, T.J.; Shepherd, L.; Au, H.J.; Langer, C.; Moore, M.J.; Zalcberg, J.R. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N. Engl. J. Med., 2008, 359, 1757-1765
4. Rehm, H.L. Disease-targeted sequencing: a cornerstone in the clinic. Nat. Rev. Genet., 2013, 14(4), 295-300.
5. Lynch, T.J.; Bell, D.W.; Sordella, R.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350, 2129-2139
6. Soda, M.; Choi, Y.L.; Enomoto, M.; Takada, S.; Yamashita, Y.; Ishikawa, S.; Fujiwara, S.; Watanabe, H.; Kurashina, K.; Hatanaka, H.; Bando, M.; Ohno, S.; Ishikawa, Y.; Aburatani, H.; Niki, T.; Sohara, Y.; Sugiyama, Y.; Mano, H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature, 2007, 448, 561-566.
7. Kwak, E.L.; Bang, Y.J.; Camidge, D.R.; Shaw, A.T.; Solomon, B.; Maki, R.G.; Ou, S.H.; Dezube, B.J.; Jänne, P.A.; Costa, D.B.; Varella-Garcia, M.; Kim, W.H.; Lynch, T.J.; Fidias, P.; Stubbs, H.; Engelman, J.A.; Sequist, L.V.; Tan, W.; Gandhi, L.; Mino-Kenudson, M.; Wei, G.C.; Shreeve, S.M.; Ratain, M.J.; Settleman, J.; Christensen, J.G.; Haber, D.A.; Wilner, K.; Salgia, R.; Shapiro, G.I.; Clark, J.W.; Iafrate, A.J. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med., 2010, 363, 1693-1703.
8. Gambacorti-Passerini, C.; Messa, C.; Pogliani, E.M. Crizotinib in anaplastic large-cell lymphoma. N. Engl. J. Med., 2011, 364, 775-776
9. Lindeman, N.I.; Cagle, P.T.; Beasley, M.B.; Chitale, D.A.; Dacic, S.; Giaccone, G.; Jenkins, R.B.; Kwiatkowski, D.J.; Saldivar, J.S.; Squire, J.; Thunnissen, E.; Ladanyi, M. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J. Mol. Diagn., 2013, 15(4), 415-453
10. Wong, S.Q.; Fellowes, A.; Doig, K.; Ellul, J.; Bosma, T.J.; Irwin, D.; Vedururu, R.; Tan, A.Y.; Weiss, J.; Chan, K.S.; Lucas, M.; Thomas, D.M.; Dobrovic, A.; Parisot, J.P.; Fox, S.B. Assessing the clinical value of targeted, massively parallel sequencing in a longitudinal, prospective population-based study of cancer patients. Br. J. Cancer, 2015, 112, 1411-1420.
11. King, M.C.; Marks, J.H.; Mandell, J.B. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science, 2003, 302(5645), 643-646.
12. Jones, S.; Hruban, R.H.; Kamiyama, M.; Borges, M.; Zhang, X.; Parsons, D.W.; Lin, J.C.; Palmisano, E.; Brune, K.; Jaffee, E.M.; Iacobuzio-Donahue, C.A.; Maitra, A.; Parmigiani, G.; Kern, S.E.; Velculescu, V.E.; Kinzler, K.W.; Vogelstein, B.; Eshleman, J.R.; Goggins, M.; Klein, A.P. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science, 2009, 324 (5924), 217
13. Mannelli, M.; Castellano, M.; Schiavi, F.; Filetti, S.; Giacchè, M.; Mori, L.; Pignataro, V.; Bernini, G.; Giachè, V.; Bacca, A.; Biondi, B.; Corona, G.; Di Trapani, G.; Grossrubatscher, E.; Reimondo, G.; Arnaldi, G.; Giacchetti, G.; Veglio, F.; Loli, P.; Colao, A; Ambrosio, M.R.; Terzolo, M.; Letizia, C.; Ercolino, T.; Opocher, G.; Italian Pheochromocytoma/Paraganglioma Network. Clinically guided genetic screening in a large cohort of Italian patients with pheo-chromocytomas and/or functional or nonfunctional paraganglio-mas. J. Clin. Endocrinol. Metab., 2009, 94, 1541-1547.
14. Yang, Y.; Muzny, D.M.; Reid, J.G.; Bainbridge, M.N.; Willis, A.; Ward, P.A.; Braxton, A.; Beuten, J.; Xia, F.; Niu, Z.; Hardison, M.; Person, R.; Bekheirnia, M.R.; Leduc, M.S.; Kirby, A.; Pham, P.; Scull, J.; Wang, M.; Ding, Y.; Plon, S.E.; Lupski, J.R.; Beaudet, A.L.; Gibbs, R.A.; Eng, CM. Clinical whole-exome sequencing for the diagnosis of mendelian disorders. N. Engl. J. Med., 2013, 369(16), 1502-1511.
15. Dewey, F.E.; Grove, M.E.; Pan, C.; Goldstein, B.A.; Bernstein, J.A.; Chaib, H.; Merker, J.D.; Goldfeder, R.L.; Enns, G.M.; David, S.P.; Pakdaman, N.; Ormond, K.E.; Caleshu, C.; Kingham, K.; Klein, T.E.; Whirl-Carrillo, M.; Sakamoto, K.; Wheeler, M.T.; Butte, A.J.; Ford, J.M.; Boxer, L.; Ioannidis, J.P.; Yeung, A.C.; Altman, R.B.; Assimes, T.L.; Snyder, M.; Ashley, E.A.; Quertermous, T. Clinical Interpretation and Implications of Whole-Genome Sequencing. JAMA, 2014, 311(10), 1035-1044.
16. Yung, R.C.; Otell, S.; Illei, P.; Clark, D.P.; Feller-Kopman, D.; Yarmus, L.; Askin, F.; Gabrielson, E.; Li, Q.K. Improvement of cellularity on cell block preparations using the socalled tissue coagulum clot method during endobronchial ultrasound-guided trans-bronchial fine-needle aspiration. Cancer Cytopathol., 2012, 120, 185-195.
17. Kanagal-Shamanna, R.; Portier, B.P.; Singh, R.R.; Routbort, M.J.; Aldape, K.D.; Handal, B.A.; Rahimi, H.; Reddy, N.G.; Barkoh, B.A.; Mishra, B.M.; Paladugu, A.V.; Manekia, J.H.; Kalhor, N.; Chowdhuri, S.R.; Staerkel, G.A.; Medeiros, L.J.; Luthra, R.; Patel, K.P. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. Mod. Pathol., 2014, 27(2), 314-327.
18. Mok, T. S. Personalized medicine in lung cancer: what we need to know. Nature Rev. Clin. Oncol., 2011, 8, 661-668.
19. Pao, W.; Hutchinson, K.E. Chipping away at the lung cancer genome. Nat. Med., 2012, 18, 349-351.
20. Scarpa, A.; Sikora, K.; Fassan, M.; Rachiglio, A.M.; Cappellesso, R.; Antonello, D.; Amato, E.; Mafficini, A.; Lambiase, M.; Esposito, C.; Bria, E.; Simonato, F.; Scardoni, M.; Turri, G.; Chilosi, M.; Tortora, G.; Fassina, A.; Normanno, N. Molecular Typing of Lung Adenocarcinoma on Cytology Samples Using a Multigene Next Generation Sequencing Panel. PLoS ONE, 2013, 8(11), e80478
21. Vigneri, R.; Malandrino, P.; Vigneri, P. The changing epidemiology of thyroid cancer: why is incidence increasing? Current Opin. Oncol., 2015, 27, 1-7.
22. Gharib, H. Changing trends in thyroid practice: understanding nodular thyroid disease. Endocr. Pract., 2004, 10(1), 31-39
23. Nikiforov, Y.E.; Nikiforova, M.N. Molecular genetics and diagnosis of thyroid cancer. Nat. Rev. Endocrinol., 2011, 7, 569-580.
24. Xing, M.; Haugen, B.R.; Schlumberger, M. Progress in molecularbased management of differentiated thyroid cancer. Lancet, 2013, 381(9871), 1058-1069.
25. Nikiforov, Y.E.; Ohori, N.P.; Hodak, S.P.; Carty, S.E.; LeBeau, S.O.; Ferris, R.L.; Yip, L.; Seethala, R.R.; Tublin, M.E.; Stang, M.T.; Coyne, C.; Johnson, J.T.; Stewart, A.F.; Nikiforova, M.N. Impact of mutational testing on the diagnosis and management of patients with cytologically indeterminate thyroid nodules: a prospective analysis of 1056 FNA samples. J. Clin. Endocrinol. Me-tab., 2011, 96, 3390-3397.
26. Nikiforova, M.N.; Wald, A.I.; Roy, S.; Durso, M.B.; Nikiforov, Y.E. Targeted next-generation sequencing panel (ThyroSeq) for detection of mutations in thyroid cancer. J. Clin. Endocrinol. Metab., 2013, 98(11), E1852-E1860.
27. Nikiforov, Y.E.; Carty, S.E.; Chiosea, S.I.; Coyne, C.; Duvvuri, U.; Ferris, R.L.; Gooding, W.E.; Hodak, S.P.; LeBeau, S.O.; Ohori, N.P.; Seethala, R.R.; Tublin, M.E.; Yip, L.; Nikiforova, M.N. Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. Cancer, 2014, 120(23), 3627-3634.
28. Le Mercier, M.; D'Haene, N.; De Nève, N.; Blanchard, O.; Degand, C.; Rorive, S.; Salmon, I. Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. Histopathology, 2015, 66(2), 215-224.
29. Ryan, D.P.; Hong, T.S.; Bardeesy, N. Pancreatic Adenocarcinoma. N. Engl. J. Med., 2014, 371, 1039-1049.
30. de Biase, D.; Visani, M.; Baccarini, P.; Polifemo, A.M.; Maimone, A.; Fornelli, A.; Giuliani, A.; Zanini, N.; Fabbri, C.; Pession, A.; Tallini, G. Next Generation sequencing improves the accuracy of KRAS Mutation analysis in endoscopic ultrasound fine needle aspiration pancreatic lesions. PLoS ONE, 2014, 9(2), e87651.
31. McCarthy, J.J.; McLeod, H.L.; Ginsburg, G.S. Genomic medicine: a decade of successes, challenges, and opportunity. Sci. Transl. Med., 2013, 5(189), 189sr4
32. Haspel, R.L.; Arnaout, R.; Briere, L.; Kantarci, S.; Marchand, K.; Tonellato, P.; Connolly, J.; Boguski, M.S.; Saffitz, J.E. A call to action: Training pathology residents in genomics and personalized medicine. Am. J. Clin. Pathol., 2010, 133, 832-834
33. ASCP. Training Residents in Genomics website. www.pathology learning.org/trig (Accessed 2010)
34. Schrijver, I.; Natkunam, Y.; Galli, S.; Boyd, S.D. Integration of genomic medicine into pathology residency training: The Stanford open curriculum. J. Mol. Diagn., 2013, 15, 141-148.
35. Landrum, M.J.; Lee, J.M.; Riley, G.R.; Jang, W.; Rubinstein, W.S.; Church, D.M.; Maglott, D.R. Clinvar: Public archive of relation-ships among sequence variation and human phenotype. Nucleic Acids Res., 2014, 42, D980-D985
36. ACMG Board of Directors. Points to consider for informed consent for genome/exome sequencing. Genet. Med., 2013, 15, 748-749
37. Green, R.C.; Berg, J.S.; Grody, W.W.; Kalia, S.S.; Korf, B.R.; Martin, C.L. ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing. Genet. Med., 2013, 15(7), 565-574.
38. ACMG updates recommendations on “opt-out” for genome sequencing return of results. American College of Medical Genetics and Genomics. www.acmg.net/docs/Release_ACMGUpdates Rec-ommendations_final.pdf (Accessed 2010)
39. Parsons, D.W.; Roy, A.; Plon, S.E.; Roychowdhury, S.; Chinnaiyan, A.M. Clinical Tumor Sequencing: An Incidental Casualty of the American College of Medical Genetics and Genomics Recommendations for Reporting of Incidental Findings. J. Clin. Oncol., 2014, 32, 2203-2205.
40. ACMG Board of Directors. ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing. Genet. Med., 2015, 17, 68-69.
41. Schrijver, I.; Aziz, N.; Farkas, D.H.; Furtado, M.; Gonzalez, A.F.; Greiner, T.C.; Grody, W.W.; Hambuch, T.; Kalman, L.; Kant, J.A.; Klein, R.D.; Leonard, D.G.; Lubin, I.M.; Mao, R.; Nagan, N.; Pratt, V.M.; Sobel, M.E.; Voelkerding, K.V.; Gibson, J.S. Opportunities and challenges associated with clinical diagnostic genome sequencing: A report of the association for molecular pathology. J. Mol. Diagn., 2012, 14, 525-540.
42. Gargis, A.S.; Kalman, L.; Berry, M.W.; Bick, D.P.; Dimmock, D.P.; Hambuch, T.; Lu, F.; Lyon, E.; Voelkerding, K.V.; Zehnbauer, B.A.; Agarwala, R.; Bennett, S.F.; Chen, B.; Chin, E.L.; Compton, J.G.; Das, S.; Farkas, D.H.; Ferber, M.J.; Funke, B.H.; Furtado, M.R.; Ganova-Raeva, L.M.; Geigenmüller, U.; Gunselman, S.J.; Hegde, M.R.; Johnson, P.L.; Kasarskis, A.; Kul- karni, S.; Lenk, T.; Liu, C.S.; Manion, M.; Manolio, T.A.; Mardis, E.R.; Merker, J.D.; Rajeevan, M.S.; Reese, M.G.; Rehm, H.L.; Simen, B.B.; Yeakley, J.M.; Zook, J.M.; Lubin, I.M. Assuring the quality of next-generation sequencing in clinical laboratory practice. Nat. Biotechnol., 2012, 30, 1033-1036.
43. Dubbink, H.J.; Deans, Z.C.; Tops, B.B.; van Kemenade, F.J.; Koljenovi, S.; van Krieken, H.J.; Blokx, W.A.; Dinjens, W.N.; Groenen, P.J. Next generation diagnostic molecular pathology: Critical appraisal of quality assurance in Europe. Mol. Oncol., 2014, 8, 830-839.
44. ACMG Board of Directors. Points to consider in the clinical application of genome sequencing. Genet. Med., 2012, 14, 759-761.
45. Rehm, H.L.; Bale, S.J.; Bayrak-Toydemir, P.; Berg, J.S.; Brown, K.K.; Deignan, J.L.; Friez, M.J.; Funke, B.H.; Hegde, M.R.; Lyon, E. Working Group of the American College of Medical Genetics and Genomics Laboratory Quality Assurance Commitee. ACMG clinical laboratory standards for next-generation sequencing. Genet. Med., 2013, 15, 733-747.
46. Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W.W.; Hegde, M.; Lyon, E.; Spector, E.; Voelkerding, K.; Rehm, H.L.; on behalf of the ACMG Laboratory Quality Assurance Committee. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet. Med., (Epub ahead of print, March 5, 2015)